Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2005

View Archived Issues

New mode of cell death achieved with novel CDK4 homologous peptide

Targeting urotensin II for CHF and restenosis following balloon angioplasty

Apoptosis-inducing metal-based complexes described by Irish scientists

Allergy Therapeutics updates status of allergy vaccine programs

Senexis and Galapagos expand collaboration

Idenix outlines plans for valopicitabine phase III trials

Positive results disclosed from MEND-CABG study of MC-1

FDA gives feedback on phase III study protocol for cethromycin in CAP

Cel-Sci signs cooperative agreement with NIAID to test CEL-1000 for bird flu

Study to investigate Phytosel's ability to lower chemotherapy side effects

UGT1A1 test launched to determine appropriate Camptosar dosage

VX-950 enters phase II development for HCV

Neuren raises funding to advance neurological compounds

Merck submits Gardasil BLA

Hylenex receives FDA approval

PXD-101: update on cancer studies

Phenoxodiol effective for malignant SCC of the cervix, vagina or vulva and advanced prostate cancer

Targeting Tie-1 for cancer

A benzodiazepine modulates c-myc

Targeting tissue factor enhances paclitaxel activity

Data on human monoclonal antibodies to TRAIL receptors

Preclinical studies show curcumin prevents breast cancer metastasis

New therapeutics for cancer disclosed in recent patents

Novel agents for alopecia, psoriasis claimed in recent patents

DailyDrugNews.com invites users to participate in Reader Survey

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.